Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Permitted use of Pharma in Focus

Pharma in Focus includes both free and protected content. Free content is available to all users. Protected content is only available to registered users.

Permitted Use of Pharma in Focus protected content

  1. Pharma in Focus protected content is for the personal use of registered users only. Registered users are those who have paid a subscription for access to protected content. Protected content is any content not made available free of charge on the Pharma in Focus site or via the Pharma in Focus News Alert email.

  2. Registered users may:

    a) Access Pharma in Focus material either from their workplace computer or at home or at a remote computer if away temporarily.

    b) Make one hard copy for personal use

    c) Use the 'email a friend' facility in keeping with condition 3(a) below

  1. Registered users may not:

    a) use the 'email a friend' facility to redistribute Pharma in Focus as a whole or in any quantity or frequency which amounts to any person having substantially the benefit of unrestricted access to Pharma in Focus without having paid a subscription or having a subscription paid on their behalf

    b) use their registered email address, or permit it to be used, to allow others gain access to Pharma in Focus

    c) redistribute Pharma in Focus material to anyone by any other means.

TOP | BACK

Special Report
Digital transformation in pharma - what's it look like?
If digital is the future for pharma businesses then getting there will call for change from the top down writes Tania Rowland.
Approvals Action
Baxalta registers new haemophilia treatment
Shire-owned Baxalta has won TGA approval for a new haemophilia A treatment under the brand name Adynovate.
Pipeline Monitor
First Parkinson's drug in a decade wins US tick
Parkinson's disease patients now have something to turn to in the 'off' period when their standard medication loses effectiveness.
Debating Point
Resources in question as TGA modernises
Most areas of the pharmaceutical sector appear to agree that modernising the TGA is a good thing but how much pressure the new requirements will place on the regulator's resources remains an issue.